Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration

Published on 02 Jan 2024
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Aflibercept 2 mg/0.05 mL prefilled syringe and vial; and

• Faricimab 6 mg/0.05 mL vial

For treating adults with visual impairment due to:

• diabetic macular oedema; and

• neovascular (wet) age-related macular degeneration.

Funding status

Aflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2025.

Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MAF for the abovementioned indications from 1 March 2024.

MAF assistance does not apply to other formulation(s) or strengths(s) of aflibercept and faricimab for treating diabetic macular oedema or neovascular age-related macular degeneration.

Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration (Updated 16 Sep 2025) [PDF, 145 KB]

PES Aflibercept and faricimab for treating diabetic macular oedema and age-related macular degeneration (Updated 16 Sep 2025) [PDF, 125 KB]